P4: NATURAL PRODUCT REGULATORS OF HYPOXIA-INDUCIBLE FACTOR-1 FOR NEUROBLASTOMA

$168,269P20FY2009RRNIH

University Of Mississippi, University MS

Investigators

Linked publications & trials

Paper 38585775 Paper 29152009 Paper 27695140 Paper 26749819 Paper 26362276 Paper 26093324 Paper 26000707 Paper 25803180 Paper 25686780 Paper 25438765 Paper 25412041 Paper 25361900 Paper 25173461 Paper 25084548 Paper 25034614 Paper 24976876 Paper 24714126 Paper 24376284 Paper 24288291 Paper 24273867 Paper 24147790 Paper 24144480 Paper 24079182 Paper 23677525 Paper 23659286 Paper 23558564 Paper 23526162 Paper 23513726 Paper 23397939 Paper 23046442 Paper 23024574 Paper 23020597 Paper 22991483 Paper 22987128 Paper 22794525 Paper 22664251 Paper 22482705 Paper 22352684 Paper 22228207 Paper 22166097 Paper 22162171 Paper 21989812 Paper 21970716 Paper 21951169 Paper 21879386 Paper 21771392 Paper 21702731 Paper 21667972 Paper 21637944 Paper 21586566 Paper 21526866 Paper 21494909 Paper 21449699 Paper 21360710 Paper 21314127 Paper 21300184 Paper 21293786 Paper 21276990 Paper 21175583 Paper 21167814 Paper 21087932 Paper 21038847 Paper 20948914 Paper 20945914 Paper 20842541 Paper 20801203 Paper 20728484 Paper 20694162 Paper 20663029 Paper 20637638 Paper 20438820 Paper 20423107 Paper 20380420 Paper 20356061 Paper 20337497 Paper 20333489 Paper 20332000 Paper 20223485 Paper 20100904 Paper 20017491 Paper 19941264 Paper 19929840 Paper 19929829 Paper 19922748 Paper 19921787 Paper 19912055 Paper 19890936 Paper 19844597 Paper 19833520 Paper 19800245 Paper 19746842 Paper 19731590 Paper 19703539 Paper 19689262 Paper 19620781 Paper 19596093 Paper 19589735 Paper 19588935 Paper 19519560 Paper 19479325

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objective of this proposed study is to investigate small molecule natural product-derived hypoxia-inducible factor-1 (HIF-1) inhibitors as potential molecular-targeted agents for the treatment of neuroblastoma, the most common pediatric solid tumor predominantly found in early childhood. The Specific Aims are: 1) to determine the effects of natural product-derived HIF-1 inhibitors on hypoxia-induced dedifferentiation in neuroblastoma cells;and 2) to evaluate the potential of natural product-derived HIF-1 inhibitors to overcome hypoxia-induced resistance to chemotherapeutic agents.

View original record on NIH RePORTER →